Kisspeptin-10 Peptide Dosage: What Human Studies Actually Used

There is no established patient dosage for kisspeptin-10. Human studies have used tightly monitored research doses and routes to measure effects on LH, FSH, testosterone, and reproductive signaling. Online “100–500 mcg” peptide charts should not be treated as validated medical dosing without a licensed clinician’s evaluation.

What should patients know before using a kisspeptin-10 dosage chart?

Kisspeptin-10 dosage charts online often mix research methods with outpatient claims. The most important fact is that no standard patient dose is established for testosterone, fertility, libido, or general wellness.

Human studies support the biology: kisspeptin-10 can stimulate luteinizing hormone, or LH, and affect gonadotropin signaling in monitored settings 1. A later study reported that chronic subcutaneous kisspeptin-10 stimulated gonadotropin secretion for 12 days in healthy men, but that still does not create a broad home-use protocol 2.

Quick facts: what is known, unknown, and not established

• Known: kisspeptin signaling is part of the hypothalamic-pituitary-gonadal axis, the hormone network that links the brain, pituitary gland, and gonads 1.
• Known: KP-10 can increase LH signaling in healthy men under research conditions 1.
• Unknown: whether outpatient KP-10 use improves fertility, libido, testosterone symptoms, or long-term health outcomes.
• Not established: a validated patient dosing chart, injection schedule, cycle length, or stack.

Why online peptide dosing charts can be misleading

A chart can look precise while leaving out the details that make the study safe: screening, lab timing, route, drug purity, adverse-event tracking, and stopping rules. That matters because reproductive hormones can shift quickly, and the same hormone change can mean different things in different patients.

This is why we treat online peptide-dose charts with caution at Chia. For more background on the peptide itself, see our plain-English guide to kisspeptin-10 peptide research.

Why research dosing is not the same as a prescription protocol

A research dose is chosen to answer a study question, not to guide a patient’s home treatment. Trials may enroll narrow groups, such as healthy men, women with PCOS, or pubertal boys, and then measure short-term hormone markers rather than long-term outcomes 3 4 5.

What is kisspeptin-10 and how does it affect reproductive hormones?

Kisspeptin-10, or KP-10, is a short peptide fragment involved in reproductive hormone signaling. It acts upstream of GnRH, and studies show it can affect LH and FSH secretion in humans 1.

Kisspeptin-10, KP-10, and metastin 45-54 explained

Kisspeptin-10 is also called KP-10 or metastin 45-54. It is part of the kisspeptin family, which comes from the KISS1 gene and signals through the kisspeptin receptor, also known as KISS1R or GPR54 10.

In plain terms, kisspeptin helps tell the reproductive hormone system when to turn on. That is why researchers study it in puberty, fertility, PCOS, hypogonadotropic hypogonadism, and hormone-axis testing 4 5.

How kisspeptin signaling relates to GnRH, LH, and FSH

The pathway is: kisspeptin signaling can stimulate gonadotropin-releasing hormone, or GnRH. GnRH then signals the pituitary gland to release gonadotropins, mainly luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH 1.

LH and FSH help regulate testosterone production, ovarian function, ovulation, and sperm production as part of the hypothalamic-pituitary-gonadal axis 1. A short-term rise in LH or FSH, however, does not prove better fertility, libido, or long-term testosterone health.

Why effects may differ by sex, age, and menstrual-cycle phase

Kisspeptin response is not one-size-fits-all. Studies suggest reproductive-axis response can differ by age in men and by hormone state in women 6 7.

In women, estrogen feedback and PCOS biology can change the way kisspeptin and neurokinin B interact with gonadotropin secretion 3 7. That is one reason a single online KP-10 dose cannot be generalized.

What kisspeptin-10 doses have been studied in humans?

KP-10 human studies have used controlled research dosing by route and study design, not consumer protocols. The useful takeaway is not “copy this dose,” but that small trials measured short-term hormone responses under close monitoring.

Human research dosing chart: route, population, study design, and outcome measured

Intravenous bolus and infusion studies

Some early human kisspeptin studies used intravenous research methods to test hormone signaling. These designs are useful for physiology because blood levels and hormone response can be watched closely, but they are not the same as a prescription plan for home use 1.

Subcutaneous research studies

Subcutaneous KP-10 has also been studied. The key human study in the supplied evidence reported gonadotropin stimulation over 12 days in healthy men, which is important but still short-term and narrow in scope 2.

Why mcg, nmol/kg, and infusion rates are not interchangeable

Different studies may report peptide exposure in micrograms, nanomoles per kilogram, or infusion rates. Those units cannot be safely converted into a patient instruction without knowing molecular weight, route, timing, concentration, monitoring plan, and the patient’s diagnosis.

Is there a standard kisspeptin-10 dosage for testosterone, fertility, or libido?

There is no standard kisspeptin-10 dosage for testosterone, fertility, or libido. Human trials show hormone-signal changes, but hormone markers are not the same as clinical outcomes.

What studies show about LH and gonadotropin response in men

In men, kisspeptin-10 has been shown to stimulate LH and increase LH pulse frequency in a clinical trial 1. That matters because LH signals the testes to make testosterone, but the study finding does not prove symptom relief, fertility improvement, or safe repeated outpatient use.

What studies show in women and PCOS research

In women with PCOS, kisspeptin and neurokinin B interactions have been studied for effects on gonadotropin secretion 3. In healthy women, research has also looked at how kisspeptin and neurokinin B interact with estrogen feedback 7.

That does not mean KP-10 is a validated fertility treatment. PCOS and infertility have many causes, and treatment decisions often require labs, cycle history, ultrasound findings, partner testing, and risk review.

Why hormone changes do not prove improved fertility, libido, or long-term outcomes

A rise in LH, FSH, testosterone, or estradiol may show that the hormone axis responded. It does not prove pregnancy rates, sperm quality, libido, mood, or long-term safety improved.

For a broader background on this peptide family, our guide to kisspeptin peptide evidence explains why mechanism is promising but not the same as a proven treatment plan.

How does kisspeptin-10 compare with kisspeptin-54?

Kisspeptin-10 and kisspeptin-54 share kisspeptin receptor biology, but they are not the same molecule. Data from kisspeptin-54 should not be automatically applied to KP-10 dosing.

Shared kisspeptin receptor biology

Both peptides signal through KISS1R, also called GPR54. This receptor is important in GnRH signaling and reproductive hormone control 10.

Differences in peptide length and research use

Kisspeptin-10 is a shorter fragment, while kisspeptin-54 is a longer peptide. A human randomized trial found that kisspeptin-54 stimulated the hypothalamic-pituitary-gonadal axis in males, but that study does not define KP-10 outpatient dosing 10.

Why data from kisspeptin-54 should not be automatically applied to kisspeptin-10

Peptide length can affect half-life, receptor exposure, route, and study design, and differences between kisspeptin peptides are one reason KP-54 findings should not be used as KP-10 dosing instructions 10. Even if two peptides act on the same receptor, they can have different dosing, timing, safety, and monitoring needs.

What are the safety concerns with kisspeptin-10?

Kisspeptin-10 safety is mainly supported by small, monitored studies, not broad real-world use. The biggest practical concern is that changing reproductive hormones without a diagnosis can create avoidable risk.

Short-term monitoring used in clinical studies

Clinical studies use planned blood draws, defined eligibility rules, adverse-event checks, and controlled timing 1 2. That structure is very different from buying a research peptide and following an online chart.

Hormone-axis risks and why lab monitoring matters

The hormone axis is a feedback system. Pushing one signal can change others, including LH, FSH, testosterone, estradiol, menstrual cycling, sperm production, and symptoms.

A clinician may need to consider pregnancy goals, cycle timing, PCOS, pituitary disease, hypogonadism, medications, testosterone therapy, hCG use, or other endocrine conditions before interpreting any hormone change.

Unknowns: repeated outpatient use, stacking, and long-term safety

The honest answer is that repeated outpatient KP-10 use is not well established. Stacking KP-10 with TRT, hCG, enclomiphene, gonadorelin, growth-hormone secretagogues, or other peptides adds uncertainty because combination-specific trials are lacking.

Can you get kisspeptin-10 through Chia?

Chia does not currently offer kisspeptin-10 in any form. This article is education-only, and there is no Chia KP-10 price, prescription path, or shipping option.

Chia does not currently offer kisspeptin-10

At Chia, we only describe an offering when it is in our live catalog. Kisspeptin-10 is not listed there, so we do not imply that our providers can prescribe it or that a pharmacy can ship it through Chia.

Why the article is education-only and not a prescribing pathway

People often find KP-10 while searching for testosterone, fertility, libido, PCOS, or peptide protocols. Our role here is to help you separate human evidence from internet dosing claims.

If you want a broader evidence overview, see our related guide on what kisspeptin does and what the research shows.

When to talk with a licensed clinician about hormone or fertility symptoms

Talk with a licensed clinician if you have low libido, irregular periods, infertility, low testosterone symptoms, delayed puberty concerns, PCOS symptoms, or questions about TRT, hCG, or fertility medication. These issues need diagnosis first, not a peptide chart.

What should you ask a clinician before considering kisspeptin-10?

Before considering KP-10, ask questions that start with diagnosis and safety. A useful visit should cover labs, goals, contraindications, monitoring, and stopping rules.

Questions about diagnosis, labs, fertility goals, and contraindications

• What diagnosis are we evaluating: PCOS, hypogonadism, hypothalamic amenorrhea, pituitary disease, medication effect, or another cause?
• Which labs should be checked before any hormone-active treatment?
• How do fertility goals change the risk-benefit discussion?
• Could pregnancy, cancer history, pituitary disease, ovarian cysts, testicular disease, or current hormone therapy change the plan?

Questions about compounded or research-use peptides

• Is this being discussed as research, off-label clinical care, or a regulated prescription medication?
• What is known about the source, sterility, potency, and handling of the peptide?
• Is there human evidence for the outcome I care about, or only hormone-marker data?

Questions about monitoring and stopping rules

• Which symptoms or lab changes would mean stopping?
• How often would LH, FSH, testosterone, estradiol, pregnancy status, or cycle data be checked?
• What side effects or hormone changes should be reported right away?
• What is the plan if the treatment does not help the actual symptom or fertility goal?

Keep reading

Peptides

Kisspeptin-10 Peptide: What Human Research Shows About Hormones, Fertility, and Safety

Peptides

Kisspeptin Peptide: What It Does, Evidence, Risks, and Access

Peptides

Kisspeptin-10: How It Works, Uses, and What the Research Says